I-Inoperable Lung Cancer Treatment 2026: New TIL & Bispecific Breakthroughs 

Ukwelashwa komdlavuza wamaphaphu okungasebenzi ngo-2026 kuguquke kakhulu ngokufika kokwelashwa kwe-Tumor-Infiltrating Lymphocyte (TIL) kanye nama-bispecific antibodies. Lawa ma-immunotherapies athuthukile anikeza ithemba elisha ezigulini ezingakwazi ukuhlinzwa ngokusebenzisa amasosha omzimba ukuze aqondise futhi abhubhise amangqamuzana omdlavuza ngokuqondile, okumaka ushintsho lwepharadigm lusuka ekwelapheni ngamakhemikhali endabuko luye emuthini wamaselula onembile.

I-Paradigm Shift Ekwelapheni Umdlavuza Wamaphaphu Okungasebenzi

Indawo ye ukwelashwa komdlavuza wamaphaphu okungasebenzi iye yaba noshintsho olukhulu eminyakeni yamuva. Ngokomlando, iziguli zazithathwa njengezingafaneleki ukuhlinzwa ngenxa yokungasebenzi kahle kwamaphaphu, isigaba esithuthukile, noma izifo eziye zabhekana nazo zazibhekene nezinketho ezilinganiselwe, ngokuvamile ezilinganiselwe ekunakekelweni kokuthopha noma ukwelashwa ngamakhemikhali okunobuthi. Kodwa-ke, umphakathi wezokwelapha manje usuyabona ukuthi “ukungasebenzi” akusho ukuthi “akulapheki.”

Amasu amanje agxile ekuguquleni izimila ezingalungiseki zibe yizo ezikwazi ukuphinda zikhipheke noma ukuzuza ukulawulwa kwezifo zesikhathi eside ngokuguqulwa kwamasosha omzimba. Ukuhlanganiswa kwe Ukwelashwa kwe-TIL futhi ama-antibodies amabili limele phambili kulokhu kuziphendukela kwemvelo. Lezi zindlela zibhekana nemikhawulo yama-checkpoint inhibitors angaphambilini ngokunikeza izindlela eziqondiswe kakhulu zokwenza.

• Ukwenza kube ngokwakho: Ukwelashwa kuya ngokuya kufanelana nokwakheka kofuzo oluthile lwesimila sesiguli.
• Ukuqina: Imithi yokwelapha esekelwe kumasosha omzimba ihlose ukuthola izimpendulo ezihlala njalo kunokuncipha kwesikhashana.
• Ubuthi Obuncishisiwe: Ama-ejenti amasha alwela ukunciphisa umonakalo ezicutshini ezinempilo uma kuqhathaniswa nezidakamizwa zendabuko eziyi-cytotoxic.

Ukuqonda lokhu kuphumelela kudinga ukujula okujulile ezindleleni zebhayoloji ezizenza zisebenze. Ngokungafani ne-chemotherapy, ehlasela wonke amangqamuzana ahlukana ngokushesha, lezi zindlela zokwelapha ezintsha zisebenza njengemicibisholo eqondisiwe, ifuna omaka abathile kumaseli omdlavuza noma ikhuphule impendulo yomdabu yokuzivikela komzimba emazingeni angakaze abonwe.

Ukuqonda I-Tumor-Infiltrating Lymphocyte (TIL) Therapy

Ukwelashwa kwe-Tumor-Infiltrating Lymphocyte (TIL) kumi njengenye yentuthuko ethembisa kakhulu ukwelashwa komdlavuza wamaphaphu okungasebenzi. Le ndlela ihlanganisa ukuvuna amangqamuzana okuzivikela omzimba afudukele esimila esigulini ngokwemvelo, awanwebe elabhorethri, futhi awabuyisele ngamanani amakhulu ukuze alwe nomdlavuza.

Indlela Yokwenza

Umgomo oyinhloko wokwelashwa kwe-TIL uncike ekutheni izimila zivame ukuqukatha ama-lymphocyte aqaphela ama-antigen omdlavuza kodwa acindezelwa yi-tumor microenvironment. Ngokukhipha lawa maseli, ososayensi bangakhetha ama-clones anamandla kakhulu.

• Isizinda: Isampula yesimila ikhishwa ngokuhlinzwa noma i-biopsy.
• Ukunwetshwa: Ama-T-cell ahlukanisiwe futhi akhuliswa phambi kwe-interleukin-2 (IL-2) ukuze andise inani labantu bawo ngokuqhubekayo.
• Ukufakwa kabusha: Ngemva kokuba isiguli senza inkambo emfushane yokwelapha ngamakhemikhali ukuze kuhlanzeke amangqamuzana omzimba omzimba akhona, ama-TIL anwetshiwe aphindiselwa emzimbeni.

Le nqubo idlula ngempumelelo izindlela zokuvikela isimila. Ngo-2026, intuthuko ezinqubweni zokukhiqiza inciphise isikhathi esidingekayo ukuze kukhule lawa maseli, okwenza ukwelashwa kufinyeleleke ebangeni elibanzi leziguli ezinomdlavuza wamaphaphu ongewona omncane (NSCLC).

Ukusebenza Komtholampilo Kumdlavuza Wamaphaphu

Ukuhlola kwakamuva komtholampilo kusikisela ukuthi ukwelashwa kwe-TIL kungabangela izimpendulo ezihlala isikhathi eside ngisho nasezigulini ezithuthuke emigqeni eminingi yokwelapha kwangaphambili, okuhlanganisa i-PD-1/PD-L1 inhibitors. Ikhono lama-TILs lokubona uhlu olubanzi lwama-neoantigens liwenza asebenze ngokukhethekile ngokumelene namathumba ahlukahlukene avame ukugwema ukwelapha okuhlosiwe okukodwa.

Nakuba ekuqaleni kuhlotshaniswa kakhulu ne-melanoma, ukulungiswa kwemithetho ye-TIL yomdlavuza wamaphaphu kubonise imiphumela ekhuthazayo. Ukwelashwa kubhekana nenkinga yamathumba "abandayo", angenakho ukungena okubalulekile kwamasosha omzimba, ngokwethula ngokwenziwa umthamo omkhulu wamasosha omzimba acushiwe ngokuqondile ekujikelezeni kwesistimu.

Ama-Antibodies Ahlukene: Indlela Yokuhloswe Okukabili

Amasosha omzimba angama-Bispecific amelela enye insika yesimanje ukwelashwa komdlavuza wamaphaphu okungasebenzi. Ngokungafani namasosha omzimba e-monoclonal abophezela ku-antigen eyodwa, ama-bispecifics akhiwe ukuze abophe okuhlosiwe okubili okuhlukene ngesikhathi esisodwa. Leli khono lokubopha kabili libavumela ukuthi bahlanganise amaseli omzimba ngamaseli omdlavuza, kube lula ukubulawa okuqondile.

Isebenza kanjani i-Bispecifics

Ukucushwa okuvame kakhulu kumdlavuza wamaphaphu kubandakanya ukubophezela ku-CD3 kuma-T-cell kanye ne-antigen ethile ehambisana nesimila kuseli lomdlavuza, njenge-EGFR noma i-MET. Lokhu kuxhumana okungokomzimba kuphoqa i-T-cell ukuthi isebenze futhi ikhulule ama-cytotoxic granules ngqo kuseli lesimila.

• Ukwakhiwa kwe-Synapse: I-antibody idala i-synapse ye-immunological phakathi kwe-T-cell neseli lomdlavuza.
• Ukwenza kusebenze: Lokhu kuba seduze kubangela ukusebenza kwe-T-cell ngaphandle kokukhawulelwa kwe-MHC.
• Ukubulala: Ingqamuzana lomdlavuza li-lysed kahle, lidlula izindlela eziningi zokumelana.

Le nqubo ibaluleke kakhulu ezigulini ezinamathumba ehlise ama-molecule ekilasi I le-MHC, umzila ojwayelekile wokuphunyuka kumdlavuza ozama ukucashela amasosha omzimba. Amasosha omzimba ayi-Bispecific awanciki ekwethulweni kwemvelo kwama-antigen ngendlela efanayo, ehlinzeka ngenye indlela eqinile yokubhujiswa kwamasosha omzimba.

Izinzuzo Ngaphezu Kwe-Immunotherapy Yendabuko

Ama-checkpoint inhibitors endabuko asebenza ngokukhulula amabhuleki amasosha omzimba, ngethemba lokuthi ama-T-cell akhona azohlasela isimila. I-Bispecifics, nokho, iqhuba ukuhlasela. Le ndlela yokusebenza ingabalulekile ezigulini ezinomthwalo ophansi we-tumor mutational (TMB) ezivame ukuphendula kabi ekuvinjweni kwendawo yokuhlola zizodwa.

Ngaphezu kwalokho, uhhafu wempilo kanye neshejuli yomthamo wezinto ezintsha ezintsha ze-bispecific ziye zaba ngcono, okuvumela ukuphathwa kweziguli ezingalaliswanga ezimweni eziningi. Lokhu kunciphisa umthwalo ezigulini esezivele zibhekene nenkinga engokomzimba yesifo esithuthukile samaphaphu.

Ukuhlaziywa Okuqhathanisayo Kwemithi Yokwelapha Esafufusa

Ukuze uqonde lapho ukwelashwa kwe-TIL kanye namasosha omzimba e-bispecific kungena ngaphakathi kwe-algorithm yokwelapha ebanzi, kubalulekile ukuwaqhathanisa namazinga akhona okunakekela. Ithebula elilandelayo libonisa umehluko oyinhloko endleleni, ukusetshenziswa, kanye nezinzuzo ezingaba khona.

Lesi siqhathaniso sigqamisa ukuthi akukho ukwelashwa okukodwa okudlula yonke indawo. Esikhundleni salokho, inkambiso yango-2026 isibheke amasu alandelanayo noma ahlangene. Isibonelo, isiguli singase sithole ukwelashwa ngamakhemikhali ukuze kuncishiswe inqwaba yesimila, kulandelwe i-antibody ye-bispecific ukuze kuhlanzeke isifo esisele, noma ukwelashwa kwe-TIL njengendlela yokusindisa ngemva kokwehluleka kwamanye ama-immunotherapies.

Amasu Ahlanganisiwe Okusebenza Okukhulu

Ikusasa le ukwelashwa komdlavuza wamaphaphu okungasebenzi ayitholakali ku-monotherapy kodwa ezinhlanganisela ezihlakaniphile. Abacwaningi bahlola ngenkuthalo ukuthi bangapakisha kanjani lezi zindlela ukuze banqobe ukumelana nokujulisa izimpendulo.

I-TILs Plus Checkpoint Inhibition

Ngisho nangemva kokufakwa kabusha, ama-TIL angaphelelwa amandla ngaphakathi kwe-tumor microenvironment. Ukuhlanganisa ukwelashwa kwe-TIL nama-PD-1 inhibitors kusiza ukugcina umsebenzi wamaseli afakiwe. Idatha yangaphambi kwesikhathi iphakamisa ukuthi le nhlanganisela inganweba ukusinda okungenantuthuko ngokuphawulekayo uma kuqhathaniswa nanoma iyiphi i-ejenti yodwa.

I-Bispecifics nge-Chemotherapy

I-Chemotherapy ingabangela ukufa kwamangqamuzana e-immunogenic, ikhulule ama-antigen amaningi e-tumor futhi yenze isimila sibonakale kakhudlwana amasosha omzimba. Uma kubhangqwe namasosha omzimba angama-bispecific, lokhu kungakha umthelela we-synergistic lapho ukwelashwa ngamakhemikhali kuqala imvelo, futhi i-bispecific ishayela ukubulala.

• Ukulandelanisa izindaba: Uhlelo okulawulwa ngalo ukwelashwa lungathinta ukusebenza kahle.
• Ukulawula Ubuthi: Ukuhlanganisa ama-activators omzimba anamandla kudinga ukuqapha ngokucophelela i-cytokine release syndrome (CRS).
• Ukukhetha Kwesiguli: Ukuhlolwa kwe-Biomarker kubalulekile ukuze kutholakale ukuthi iyiphi inhlanganisela enikeza isilinganiso esingcono kakhulu senzuzo yengozi.

Izivivinyo zemitholampilo ngo-2026 zigxila kakhulu kumiklamo eguquguqukayo, lapho ukwelashwa kungashintshwa noma kwengezwe ngokusekelwe kumamethrikhi okuphendula kusenesikhathi. Le ndlela eguquguqukayo iqinisekisa ukuthi iziguli zithola uhlobo olusebenza kahle kakhulu ngesikhathi esifanele.

Izinselelo Nemikhawulo Kumaphrothokholi Amanje

Naphezu kwesasasa elizungeze le mpumelelo, izinselele ezinkulu zisekhona ekwamukelweni okusabalele kwe-TIL kanye nokwelapha okuyi-bispecific for umdlavuza wamaphaphu ongasebenzi. Ukuvuma lezi zithiyo kubalulekile ekubekeni okulindelekile okungokoqobo.

Ukukhiqiza kanye Logistics

Ukwelashwa kwe-TIL kuyinkimbinkimbi kakhulu futhi kudinga izinsiza. Idinga izinsiza ezikhethekile zokucutshungulwa kwamaseli kanye nezivumelwano eziqinile zokugcinwa kwazo. Isikhathi kusuka ku-biopsy kuya ekufakweni kungathatha amasonto ambalwa, okungase kube yinde kakhulu ezigulini ezinesifo esikhula ngokushesha. Imizamo iyaqhubeka yokwenza le nqubo ibe lula, kodwa izithiyo zokuhlela ziyaqhubeka.

Amaphrofayili Wobuthi

Kokubili ukwelashwa kwe-TIL kanye namasosha omzimba aphethe izingozi zobuthi eziyingqayizivele. Ukwelashwa kwe-TIL kuvame ukudinga umthamo ophezulu we-IL-2, ongabangela i-capillary leak syndrome kanye ne-hypotension. Ama-Bispecifics ahlotshaniswa ne-Cytokine Release Syndrome (CRS) kanye ne-neurotoxicity. Ukuphatha le miphumela emibi kudinga amaqembu okunakekelwa kwezempilo anolwazi futhi ngokuvamile ukulaliswa esibhedlela phakathi nezigaba zokuqala zokwelashwa.

• Ukuphathwa kwe-CRS: Idinga ukungenelela ngokushesha nge-tocilizumab noma i-steroids.
• Imiphumela Yesikhathi eside: Izenzakalo ze-Autoimmune zingenzeka ezinyangeni ngemva kokwelashwa.
• Ukufaneleka Kwesiguli: Iziguli ezibuthaka zingase zingakubekezeleli ukushuba kwalezi zinhlobo zemithi.

Izindleko Nokufinyeleleka

Izindleko eziphezulu zokuthuthukisa kanye nokuphatha izindlela zokwelapha eziqondene nomuntu siqu zamaselula zibeka isithiyo esibalulekile ekufinyeleleni. Ukuhlinzekwa komshwalense kuyehluka kakhulu, futhi ezifundeni eziningi, lokhu kwelashwa kuhlala kutholakala kuphela ngezivivinyo zomtholampilo noma izikhungo ezikhethekile. Ukufinyelela ngokulinganayo kusewumgomo obalulekile womphakathi we-oncology womhlaba wonke.

Ukukhethwa Kwesiguli Nokuhlolwa Kwe-Biomarker

Iphumelele ukwelashwa komdlavuza wamaphaphu okungasebenzi kuncike ekukhetheni isiguli okunembile. Akuzona zonke iziguli ezizohlomula ku-TIL noma kuma-bispecific therapy, okwenza ukuhlolwa kwe-biomarker kube yisinyathelo esibalulekile ekuhambeni komsebenzi womtholampilo.

Ama-Biomarker Abalulekile Okufanele Ahlolwe

Odokotela manje babheka ngale kwe-histology elula. Iphrofayili ye-genomic ebanzi iwumkhuba ojwayelekile wokuhlonza izinguquko ezingenzeka kanye namasignesha omzimba.

• I-PD-L1 Expression: Nakuba ibikezela kancane kuma-TIL, ihlala ihambisana namasu ahlanganisiwe.
• I-Tumor Mutational Burden (TMB): I-TMB ephakeme ivamise ukuhlobana nokusabela okungcono ekwelashweni okusekelwe kumasosha omzimba.
• Ama-Antigen athile: Ukuba khona kokuhlosiwe okufana ne-EGFR, i-MET, noma i-KRAS kubalulekile ukuze uvumeleke kabili.
• Ukuthayipha kwe-HLA: Ama-allele athile e-HLA angase abe nomthelela empumelelweni yokuqashelwa kwe-TIL.

Iqhaza Le-Liquid Biopsy

Ama-Liquid biopsies, ahlaziya i-DNA yesimila esijikelezayo (ctDNA), aya ngokuya ebaluleka. Banikeza indlela engahlaseli yokuqapha impendulo yokwelashwa kanye nokuthola izinguquko ezikhulayo zokumelana ngesikhathi sangempela. Lokhu kuvumela odokotela ukuthi bashintshe amasu ngokushesha uma isiguli siyeka ukuphendula ku-bispecific noma iselula ethile.

Ukuhlanganisa la mathuluzi okuxilonga ekunakekelweni okujwayelekile kuqinisekisa ukuthi iziguli zifaniswa nokwelashwa okungenzeka ukuthi kuphumelele, kunciphisa ukuchayeka ekwelashweni okungasebenzi kanye nobuthi obungadingekile.

Isicelo Somhlaba Wangempela kanye Nezimo Zezimo

Ukukhombisa umthelela ongokoqobo walezi ntuthuko, cabangela izimo eziqanjiwe ezibonisa ukucabanga komtholampilo kwamanje ngo-2026.

Isimo A: Isiguli Eselashwe Kakhulu

Isiguli esineminyaka engu-65 esine-Stage IV NSCLC sesithuthuke nge-platinamu chemotherapy, i-immunotherapy, kanye nokwelashwa okuhlosiwe. Izinketho zokuhlinza ziphelile. Kulokhu, Ukwelashwa kwe-TIL inikeza inketho yokulondoloza esebenzayo. Ngokusebenzisa ama-neoantigens ahlukile akhona kusimila sawo esithile, ukwelashwa kunikeza umugqa omusha wokuzivikela lapho izidakamizwa ezijwayelekile zehlulekile.

Isimo B: I-Low-PD-L1 Expressor

Isiguli sinomdlavuza wamaphaphu ongasebenzi kodwa sinomqondo ophansi we-PD-L1, okubenza babe mpofu kuma-checkpoint inhibitors kuphela. Lapha, a i-bispecific antibody ukukhomba i-antigen yendawo evame kakhulu kungaba ukukhetha okuyinhloko. Ikhono layo lokubandakanya ama-T-cell ngaphandle kwesimo se-PD-L1 linikeza inzuzo yemishini edlula umkhawulo wokuvezwa komaka ophansi.

Lezi zimo zigcizelela ukubaluleka kwendlela yebhodi yesimila ehlukahlukene. Izinqumo mayelana ukwelashwa komdlavuza wamaphaphu okungasebenzi azisalingani kodwa zibandakanya izihlahla zesinqumo eziyinkimbinkimbi ezisekelwe kumaphrofayili amangqamuzana nesimo sokusebenza kwesiguli.

Izikhombisi-ndlela zesikhathi esizayo kanye nocwaningo oluqhubekayo

Umkhakha wezokwelapha umdlavuza wamaphaphu uhamba ngesivinini esikhulu. Njengoba sibheka ngale kuka-2026, amathrendi ambalwa asafufusa athembisa ukuqhubeka nokucwengwa ukwelashwa komdlavuza wamaphaphu okungasebenzi.

Imithi Yokwelapha Yeseli Yesizukulwane Esilandelayo

Ucwaningo lushintshela emikhiqizweni ye-TIL “engaphandle kweshalofu”, ezoqeda isidingo sokubambezeleka kokukhiqiza okuqondene nesiguli. Ukwengeza, amaseli e-T ahlelwe ngofuzo aklanyelwe ukumelana nokukhathala noma ukukhiqiza ama-cytokines engeziwe asathuthuka, okuhloswe ngawo ukuthuthukisa ukuphikelela namandla.

I-Artificial Intelligence Ekuhleleni Ukwelashwa

Ama-algorithms e-AI aya ngokuya esetshenziswa ukubikezela ukuthi yiziphi iziguli ezizosabela kuma-immunotherapies athile. Ngokuhlaziya amasethi edatha amaningi olwazi lwe-genomic nolwazi lomtholampilo, lawa mamodeli angasiza izazi ze-oncologist ukuklama inhlanganisela yemithi yomuntu siqu enamathuba aphezulu okuphumelela.

• Ukumodela Okuqagelayo: Ukubikezela izingozi zobuthi ngaphambi kokuqala kokwelashwa.
• Ukutholwa Kwezidakamizwa: Ukuhlonza okuphokophelwe inoveli okuyi-bispecific ngokushesha kunezindlela zendabuko.
• Ukufana Kwesivivinyo: Ukuxhuma iziguli ngezivivinyo zomtholampilo ezifanele ngokushesha.

Ukwandisa Izinkomba

Nakuba okwamanje kugxilwe ezigabeni ezithuthukisiwe, kunentshisekelo ekhulayo yokuhambisa lezi zindlela zokwelapha ngaphambi kwesikhathi esimisweni sesifo, okungenzeka ukuthi zisetshenziswe i-neoadjuvant ezimweni ezibuyekezwa emngceleni. Ukuguqula izimila ezingasebenzi ukuthi zisebenze kusewumgomo omkhulu wabacwaningi abaningi.

Imibuzo Evame Ukubuzwa

Iziguli kanye nemindeni bavame ukuba nemibuzo enzima mayelana nalokhu kwelashwa okusha. Ukusingatha izinto ezikhathazayo ezivamile kusiza ukufingqa inqubo futhi kunikeza amandla okwenza izinqumo ezinolwazi.

Ingabe ukwelashwa kwe-TIL kubuhlungu?

Ukuqoqwa kwezicubu zesimila kudinga inqubo engase ihilele ukungakhululeki, elawulwa nge-anesthesia. I-infusion ngokwayo ifana nokumpontshelwa igazi. Kodwa-ke, i-chemotherapy yokulungiselela kanye nokuphathwa kwe-IL-2 kungabangela imiphumela emibi edinga ukuphathwa ngokucophelela.

Kuthatha isikhathi esingakanani ukubona imiphumela?

Izikhathi zokuphendula ziyahlukahluka. Ezinye iziguli zibona ukuncipha kwesimila kungakapheli amasonto emukelwe, kanti ezinye zingase zibe nesifo esizinzile izinyanga ngaphambi kokuqhubekela phambili. Ukuthwebula izithombe okuvamile nokuhlolwa kwegazi kusetshenziselwa ukuqapha ukusebenza kahle.

Ingabe lezi zindlela zokwelapha zikhokhelwa umshwalense?

Ukufakwa kuyehluka ngokwesifunda kanye nomhlinzeki womshwalense othile. Njengoba ukugunyazwa kwanda futhi idatha yomtholampilo ikhula, izinqubomgomo zokubuyisela ziyathuthuka. Iziguli zikhuthazwa ukuthi zixhumane nabeluleki bezezimali ezikhungweni zabo zokwelashwa.

Isiphetho: Inkathi Entsha Yethemba

Unyaka wezi-2026 uphawula inguquko eqinisekile ekuphathweni kwe umdlavuza wamaphaphu ongasebenzi. Ukuhlangana kwe Ukwelashwa kwe-TIL futhi ama-antibodies amabili uye wandisa izikhali zokwelapha, enikeza ithemba eliphathekayo ezigulini ebezinezinketho ezimbalwa ngaphambilini. Nakuba izinselele eziphathelene nezindleko, ubuthi, kanye nokusetshenziswa kwezinto zisekhona, umzila umihle ngokusobala.

Lezi zindlela ezintsha ziyisibonelo sokushintshela emuthini onembayo, lapho ukwelapha kuhambisana nesiginesha yebhayoloji eyingqayizivele yesifo sesiguli ngasinye. Njengoba ucwaningo luqhubeka nokucwenga lezi zindlela futhi luzihlanganise nokuxilongwa okuqhutshwa yi-AI, incazelo yokuthi "ukungasebenzi" ingase iqhubeke nokuncipha.

Ezigulini nakubanakekeli, ukuhlala unolwazi ngalezi ntuthuko kubalulekile. Ukuxhumana nodokotela be-oncologists mayelana nokufaneleka kwe-TIL noma ukuhlolwa kwe-bispecific kungavula iminyango yezindlela zokwelapha ezinweba impilo. Uhambo lokulwa nomdlavuza wamaphaphu lunzima, kodwa amathuluzi atholakalayo namuhla anamandla futhi anembe kakhulu kunangaphambili.

• Hlala unolwazi: Qhubeka nemiphumela yakamuva yesilingo somtholampilo.
• Buza Imibuzo: Xoxa ngesivivinyo se-biomarker nezinketho zokwelapha ezinoveli nethimba lakho lokunakekela.
• Funa Usekelo: Xhumana namaqembu amelela isiguli angochwepheshe be-immunotherapy yomdlavuza wamaphaphu.

Indlela eya phambili ikhanyiswa ubuhlakani besayensi nokuzinikela komtholampilo. Ngawo wonke ukuphumelela ukwelashwa komdlavuza wamaphaphu okungasebenzi, sisondela esikhathini esizayo lapho lokhu kuxilongwa kungaselona umusho obulalayo kodwa isimo esilawulekayo esingamahlalakhona noma ngisho isifo esilaphekayo.